Zhejiang Benli Technology Co Ltd

Zhejiang Benli Technology Co Ltd maintains a strong liquidity position, with a current ratio of 3.97, indicating that it has nearly four times as many current assets as current liabilities. The company's liquidity_fpt score suggests that it is well-positioned to meet short-term obligations, although its net cash position is negative after subtracting total debt, which introduces a medium liquidity risk.

In terms of profitability, the company reported a net income of CNY 24,906,190 and a return on equity (ROE) of 1.95%, which is below the typical industry benchmark for pharmaceutical firms. Its return on assets (ROA) of 1.61% also lags behind the median for its industry, suggesting that the company is not generating strong returns relative to its asset base.

The company's revenue is concentrated in a single geographic market, China, and it does not disclose segment-level revenue breakdowns in its latest financials. This lack of diversification increases its exposure to domestic regulatory and economic shifts.

Looking ahead, the company's revenue is expected to grow, though the exact rate is not disclosed. Historical revenue growth has been modest, and the company's capital expenditures have been negative, indicating asset disposals or a reduction in investment.

The company's risk profile is characterized by a low dilution potential, as there is no indication of recent or planned share issuance. However, the negative net cash position and the presence of long-term debt, albeit small, suggest that the company may need to raise capital in the future, which could introduce dilution risk.

Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company appears to be maintaining a stable but conservative financial strategy, with no significant capital outlays or new market entries disclosed in the latest available data.

Net income surged 22.1% year-over-year to CNY 78.8 million, demonstrating strong profitability growth despite revenue headwinds.

Operating income increased 20.0% to CNY 90.8 million, indicating improved core operational efficiency and cost management.

Cash conversion ratio of 6.87 is best-in-class, vastly exceeding the cohort median of 0.95 and signaling superior cash generation.

The company maintains a zero debt-to-equity ratio, providing a pristine balance sheet with minimal financial leverage risk.

Revenue declined 9.9% year-over-year to CNY 638.5 million, highlighting significant top-line contraction and market share pressure.

Medium liquidity risk flags suggest potential challenges in meeting short-term obligations or maintaining adequate cash buffers.

Revenue CAGR of only 0.7% over four years indicates stagnant long-term growth trajectory compared to industry peers.